127 related articles for article (PubMed ID: 34845315)
1. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.
Kongkiatkamon S; Pagliuca S; Adema V; Nagata Y; Kerr CM; Walter W; Awada H; Hutter S; Gurnari C; Rogers HJ; Meggendorfer M; Saunthararajah Y; Haferlach T; Visconte V; Maciejewski JP
Leukemia; 2022 Apr; 36(4):1185-1188. PubMed ID: 34845315
[No Abstract] [Full Text] [Related]
2. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Andersen CL; Hasselbalch H; Grønbæk K
Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
[TBL] [Abstract][Full Text] [Related]
3. Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain.
Cross E; Duncan-Flavell PJ; Howarth RJ; Hobbs JI; Thomas NS; Bunyan DJ
Am J Med Genet A; 2020 Nov; 182(11):2508-2520. PubMed ID: 32827181
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
5. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
6. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
7. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
[TBL] [Abstract][Full Text] [Related]
8. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas P; Mortazavi A; Picus J; Hahn NM; Milowsky MI; Hart LL; Alva A; Bellmunt J; Pal SK; Bambury RM; O'Donnell PH; Gupta S; Guancial EA; Sonpavde GP; Faltaos D; Potvin D; Christensen JG; Chao RC; Rosenberg JE
Cancer; 2019 Feb; 125(4):533-540. PubMed ID: 30570744
[TBL] [Abstract][Full Text] [Related]
9. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
10. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
11. CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
Bommi-Reddy A; Park-Chouinard S; Mayhew DN; Terzo E; Hingway A; Steinbaugh MJ; Wilson JE; Sims RJ; Conery AR
PLoS One; 2022; 17(3):e0262378. PubMed ID: 35353838
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
Attar N; Kurdistani SK
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
14. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract][Full Text] [Related]
15. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
[TBL] [Abstract][Full Text] [Related]
16. Rubinstein-Taybi syndrome (CREBBP, EP300).
van Belzen M; Bartsch O; Lacombe D; Peters DJ; Hennekam RC
Eur J Hum Genet; 2011 Jan; 19(1):preceeding 118-20. PubMed ID: 20664634
[No Abstract] [Full Text] [Related]
17. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
19. Rubinstein-Taybi syndrome: clinical and molecular overview.
Roelfsema JH; Peters DJ
Expert Rev Mol Med; 2007 Aug; 9(23):1-16. PubMed ID: 17942008
[TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors.
Crawford MC; Tripu DR; Barritt SA; Jing Y; Gallimore D; Kales SC; Bhanu NV; Xiong Y; Fang Y; Butler KAT; LeClair CA; Coussens NP; Simeonov A; Garcia BA; Dibble CC; Meier JL
ACS Chem Biol; 2023 Oct; 18(10):2249-2258. PubMed ID: 37737090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
